Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Proposed period of release:
01/12/2020 to 30/06/2021

Name of the Institute(s) or Company(ies)
Janssen Vaccines & Prevention B.V., Archimedesweg 4-6
2333CP Leiden, The Netherlands;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
The identity of the GMO is Ad26.COV2.S and is a replication incompetent adenovirus vector containing the sequence for the spike (S) protein of SARS-CoV-2. The Ad26.COV2.S vector is derived from the human adenovirus group D type 26 (genus Mastadenoviridae).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Ad26MastadenovirusHuman adenovirus group DN/AType 26N/A

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known